Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice.
Gencay YE, Jasinskytė D, Robert C, Semsey S, Martínez V, Petersen AØ, Brunner K, de Santiago Torio A, Salazar A, Turcu IC, Eriksen MK, Koval L, Takos A, Pascal R, Schou TS, Bayer L, Bryde T, Johansen KC, Bak EG, Smrekar F, Doyle TB, Satlin MJ, Gram A, Carvalho J, Jessen L, Hallström B, Hink J, Damholt B, Troy A, Grove M, Clube J, Grøndahl C, Haaber JK, van der Helm E, Zdravkovic M, Sommer MOA.
Gencay YE, et al.
Nat Biotechnol. 2024 Feb;42(2):265-274. doi: 10.1038/s41587-023-01759-y. Epub 2023 May 4.
Nat Biotechnol. 2024.
PMID: 37142704
Free PMC article.